We believe our cellular immunotherapy is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type.
We are engineering 15 unique HLA types (molecules) into Bria-IMT™, collectively referred to as Bria-OTS™, allowing for matching of over 99% of patients with advanced breast cancer.
A simple saliva test is used to determine the HLA-type of each patient.
Each patient will then be treated with the appropriate pre-manufactured Bria-OTS™ formulation.
Similar cell lines are in development for prostate cancer, lung cancer, and melanoma.
A pre-clinical Cooperative Research and Development Agreement (CRADA) is in place with the National Cancer Institute (NCI) in the U.S. to investigate the Bria-OTS™ mechanism of action.
This approach allows personalized treatment without the need for personalized manufacturing. Additionally, it saves time and skips expensive and complicated manufacturing procedures associated with other personalized immunotherapy treatments.
